Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%

Bron: Yahoo Entertainment

Gepubliceerd op: 2024-12-13

XTX Topco Ltd Sells 3,111 Shares of Galapagos NV (NASDAQ:GLPG)

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-12-19

XTX Topco Ltd reduced its holdings in Galapagos NV (NASDAQ:GLPG – Free Report) by 27.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,341 shares of the biotechnology …

Galapagos NV (NASDAQ:GLPG) Given Consensus Rating of “Reduce” by Brokerages

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-12-24

Shares of Galapagos NV (NASDAQ:GLPG – Get Free Report) have received a consensus recommendation of “Reduce” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommend…

Galapagos NV (NASDAQ:GLPG) Stake Lowered by Fmr LLC

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-12-08

Fmr LLC decreased its stake in Galapagos NV (NASDAQ:GLPG – Free Report) by 44.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,598,912 shares of the biotechnology c…

Leerink Partnrs Forecasts Stronger Earnings for Galapagos

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-12-12

Galapagos NV (NASDAQ:GLPG – Free Report) – Analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Galapagos in a note issued to investors on Sunday, December 8th. Leerink Partnrs analyst F. Khurshid now forecasts that the b…

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2024-12-07

Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 6…

Galapagos kondigt bemoedigende nieuwe resultaten aan van de lopende fase 1/2-studie van de CD19 CAR T-celtherapie GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2024-12-07

Mechelen, België; 7 december 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag bijkomende resultaten aan van de lopende fase 1/2 ATALANTA-1 studie van zijn CD19 CAR T-celtherapie, GLPG5101. De resultaten, gepresenteerd tijdens een monde…

Financial Analysis: Immatics (NASDAQ:IMTX) vs. Gilead Sciences (NASDAQ:GILD)

Bron: ETF Daily News

Autheur: MarketBeat News

Gepubliceerd op: 2024-12-17

Gilead Sciences (NASDAQ:GILD – Get Free Report) and Immatics (NASDAQ:IMTX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, in…